A humanized murine model was developed to study T cell tolerance to the hepatitis B surface antigen (HBsAg) that is present in sera of hepatitis B virus chronic carriers. The HBsAg/HLA-A2 double-transgenic mice express a chimeric HLA-A2 MHC class I molecule and a high amount of the HBsAg in the liver that is secreted and present in sera during the animal's lifetime. In these mice, injection of plasmid DNA encoding HBsAg induced a high frequency of CD8 + T cells secreting IFN-g in the periphery, with in vitro cytolytic activity and speci®city for two dominant HBs-speci®c HLA-A2-restricted epitopes. Nevertheless, the DNA-based immunization elicited neither T h 1 nor T h 2 CD4 + T cell responses. Despite a high concentration of HBsAg in sera, these mice developed an immunocompetent CD8 + T cell repertoire towards the viral self-antigen, whereas the CD4 + T cell repertoire was tolerized. In the absence of a CD4 + T cell response, the IFN-g-secreting CD8 + T cells primed by DNA-based immunization were unable to exert their antiviral functions in vivo on liver cells expressing the transgene product. However, when pro-in¯ammatory stimuli were given before or after DNA-based immunization, the HBsAg was cleared from the serum. This effect was antibody dependent and associated with the detection of an HBs-speci®c T h 1 CD4 + T cell response in the periphery. This model provides evidence that HBsAg displayed a strong tolerogenic effect on the CD4 + T cell compartment that is associated with a defect in CD8 + T cell effector functions in vivo.
Introduction
Transgenic models have been developed to study the mechanisms of tolerance and their implications for immune-mediated diseases. Expression of neo-self-antigens in the liver presents a particular interest because of the putative tolerogenic role of the liver in the immune response (1±3) and because of the direct access of hepatocytes to circulating T cells (4) . In addition to central thymic selection, peripheral tolerance mechanisms that include deletion, anergy or ignorance have been de®ned. In situations where peripheral anergy or ignorance are involved, tolerance at the T cell level can be broken by using either viral infection, activated dendritic cell injection or DNA-based immunization (5, 6) .
The mechanisms responsible for T cell hypo-responsiveness or tolerance to hepatitis B virus (HBV) proteins in chronic HBV infection are not completely understood. In chronically infected patients, the CD8 + T cell response is undetectable or weak and narrow in the periphery (7) , and the CD4 + T cell response is much less vigorous than in patients with acute hepatitis (8, 9) . In children born to infected mothers, HBV antigens are considered as self-antigens and this may explain the high rate of chronic infection in this population. Thus, in people who are chronically infected, the immune response should be switched from tolerance or peripheral anergy to priming of effector T cells. To achieve this goal, antigenspeci®c immunotherapy is a promising approach in inducing ef®cient cellular immune responses. Here we have developed a novel animal model for HBV chronic carriers. The hepatitis B surface antigen (HBsAg)/HLA-A2 mouse is a humanized lineage that has as unique MHC class I molecule, the human HLA-A2 molecule (10) , and expresses HBV envelope proteins in hepatocytes. This lineage was derived from an HBsAg transgenic mouse (6) , in which we have previously reported that immunological tolerance to HBsAg can be broken by injection of a DNA vector encoding HBsAg. The HBsAg/HLA-A2 mouse allows us to investigate the induction of CD8 + T cells with speci®cities comparable to those observed in humans in the presence of a high level of circulating antigen.
In this study, the role of HBsAg in T cell tolerance was further clari®ed. We showed that peripheral speci®c cytotoxic CD8 + T cells could be primed by DNA-based immunization in a tolerant environment, whereas HBsAg-speci®c CD4 + T cells were not detectable under the same experimental conditions. In the absence of speci®c T h cells, these CD8 + T cells were unable to modulate HBsAg mRNA expression or to mediate immune injury in the liver. Clearance of circulating HBsAg by inducing anti-HBs antibodies (anti-HBs) was also not achieved. However, a pro-in¯ammatory signal, such as irradiation or CpG-containing oligonucleotides, led to a partial restoration of antiviral effector functions in vivo by enabling clearance of the antigen produced by the liver. Finally, we provided some evidence that, in this model, CD4 + T cell tolerance was maintained by the presence of circulating HBsAg.
Methods

Mice
The HBsAg/HLA-A2 double-transgenic mice were obtained from an intermediate HBsAg transgenic and MHC class I knockout lineage. HBsAg transgenic mice were previously described [E36 lineage (11) ]. To obtain HBsAg transgenic and MHC class I knockout mice, males from the E36 lineage (6, 11) were bred with MHC class I-de®cient females (12) until a founder male knockout for the b 2 -microglobulin (b 2 m ±/± ) and the D b (D b±/± ) MHC class I encoding genes and expressing HBsAg was produced. The inactivation of b 2 -microglobulin and the D b genes was con®rmed by Southern blot. Then founder males were mated with mice transgenic for a chimeric HLA-A2 molecule (HHD) and de®cient for mouse MHC class I molecules [HHD +/+ b 2 m ±/± D b±/± (10) ]. This breeding resulted in the B8HHD lineage characterized by de®ciency in mouse MHC class I molecules, low-level expression of human HLA-A2 MHC class I molecule on the surface of all cells including hepatocytes [(10) and data not shown] and expression of HBsAg in the liver. In this lineage, 50% of progeny expresses the HBV transgene due to the heterozygous status of the transgene. HBsAg ± HLA-A2 + mice were used as controls for immunization. All experiments involving animals were performed according to European guidelines.
DNA vectors and immunization
pCMV-S2.S (13) encodes the small (S) and middle (preS2+S) proteins of the HBV envelope (ayw subtype) under the control of the cytomegalovirus (CMV) immediate early gene promoter. The pMAS-core plasmid (a kind gift of H. L. Davis) used as control DNA encodes the HBV capsid. The plasmid DNA used for gene transfer was puri®ed using anion-exchange chromatography columns (Qiagen, Hilden, Germany), dissolved in endotoxin-free PBS (Sigma, St Louis, MO) at 1 mg/ml and stored at or below ±20°C. HBsAg + and HBsAg ± littermate HLA-A2 female mice, 6±8 weeks old, were immunized 1 or 2 times at 2±3 weeks interval by intramuscular injection bilaterally into cardiotoxin-treated tibialis anterior muscles as previously described (14, 15) with 100 mg of recombinant plasmid DNA. All intramuscular injections were carried out under anesthesia (sodium pentobarbital, 75 mg/kg, i.p.).
CpG oligodeoxynucleotide (ODN) (sequence 1826: 5¢-TCCATGACGTTCCTGACGTT-3¢) or non-CpG control ODN (sequence 1982: 5¢-TCCAGGACTTCTCTCAGGTT-3¢) (16) were provided by Coley (Wellesley, MA) and were synthesized with a nuclease-resistant phosphorothioate backbone. ODN were injected i.p. (50 mg in 200 ml of PBS per mouse) 1 week after the DNA booster injection. Sublethal irradiation (500 rad) prior to immunization was performed 3 days before DNA injection, when required.
Serology
Blood was collected from mice by retrobulbar puncture using heparinized glass pipettes at various times before and after DNA injection or adoptive transfer, and sera recovered by centrifugation were assayed for anti-HBs antibodies by speci®c ELISA as previously described (17) . The sera from DNAimmunized or non-immunized HBsAg/HLA-A2 transgenic mice were also used for detection of HBsAg by a commercial ELISA kit (Monolisa AgHBs Plus; Bio-Rad, Marnes la Coquette, France).
Hepatocellular injury was monitored biochemically as serum alanine transferase (ALT) activity using a commercial kit (Enzyline; BioMe Â rieux, Lyon, France).
ELISPOT assay
IFN-g-releasing cells were quanti®ed ex vivo after a short-term peptide or protein stimulation as previously described (18) . Freshly isolated splenocytes (1 Q 10 6 cells/well) were incubated in anti-IFN-g-coated wells for 40 h using different antigenic stimulations in aMEM medium (Life Technologies, Cergy-Pontoise, France). Cells were incubated either with HBV-derived HLA-A*0201-restricted epitopic peptides (HBs 183±191 , FLLTRILTI, HBs 348±357 , GLSPTVWLSV and HBc 18±27 , FLPSDFFPSV, 2 mg/ml), with I-A b -restricted preS2-derived peptide (HBs 126±138 , RGLYFPAGGSSSG, 3 mg/ml), with HBc-derived peptide (HBc 128±140 , TPPATRPPNAPIL, 3 mg/ml) or with recombinant HBsAg particles produced in mammalian cells [3 mg/ml; Aventis Pasteur, France (19) ]. Alternatively cells were infected with recombinant vaccinia virus encoding the large HBV envelope protein [rVVS1.S2.S (18) ] at the multiplicity of infection of 1/1. Wells containing cells in culture medium or infected with wild type vaccinia virus were used as negative controls to evaluate background level. Spot-forming cells (SFC) were revealed with secondary biotinconjugated antibody and with BCIP + NBT substrates (Promega, Madison, WI). Spots were counted in a doubleblind fashion under a stereo binocular. The number of speci®c IFN-g-secreting T cells was obtained by subtracting the number of spots in control wells from spots obtained after speci®c stimulation. The response measured by ELISPOT was considered signi®cant when the number of speci®c spots was >10 spots and at least 2 times higher than background. Quanti®cation of CD8 + T cells in splenocytes was performed by cyto¯uorometry analysis using a FACScan¯ow cytometer (Becton Dickinson, Sunnyvale, CA) with CellQuest software, following staining with FITC-or phycoerythrin-conjugated antimAb (PharMingen, San Diego, CA).
Measurement of cytotoxic T lymphocyte (CTL) activity
CTL activity was measured 2 weeks after DNA immunization on splenocytes stimulated in vitro with peptide for 1 week as previously described (18) . Speci®c cytolytic activity of effector cells was tested in short-term 51 Cr-release assay against either RMA-S HHD target cells (10) pulsed with 10 mg/ml of HLA-A*0201 peptides derived from the HBV small envelope protein (HBs 183±191 and HBs 348±357 ) or target cells pulsed with the well-described HLA-A*0201 HBV core epitope (HBc 18±27 ) as negative control. Speci®c lysis was calculated in triplicate as (experimental ± spontaneous release)/(maximum ± spontaneous release) Q 100.
CD4 + T lymphocyte subset fractionation and adoptive transfer
Splenocytes obtained from individual naive or DNA-primed mouse were prepared for adoptive transfer by lysis of red blood cells in single-cell suspension. After 4 washes with RPMI medium, the remaining white blood cells were counted and resuspended in 200 ml of PBS. The CD4 + T cell subpopulation was isolated by positive selection using magnetic cell sorting (MACS; Miltenyi Biotec, Paris, France) with CD4 + microbeads. The purity of the CD4 + T cell was con®rmed by cyto¯uorometry analysis. The percentage of undesirable CD8 + T cells population was <0.05%. The puri®ed CD4 + T cells were pooled according to the type of immunization and resuspended in 200 ml of endotoxin-free PBS. CD4 + T cells (6±7 Q 10 6 cells) were injected into the retro-orbital cavity of recipient mice that had been sublethally irradiated (500 rad) before transfer. Quanti®cation of HBsAg-speci®c CD4 + T cells contained in the splenocyte preparation was performed by ELISPOT assay in parallel with cell transfer.
Results
HBsAg/HLA-A2 double-transgenic mice
In the HBsAg/HLA-A2 transgenic lineage, the transgene consists of a complete HBV genome deleted of the gene encoding nucleocapsid. This construct allows liver-restricted expression of the three envelope proteins under the control of internal viral promoter and enhancer. These proteins synthesized by the hepatocytes are assembled into 22-nm HBsAgcarrying empty viral particles, which are highly secreted into the serum. The level of circulating HBsAg ranges from 1000 to 6000 ng/ml depending on the mouse for 6-to 8-week-old females. Expression of HBsAg lasts from birth and slowly decreases over time due to hormonal regulation of the transgene (20) , and methylation of the transgene does not occur in this lineage over time (21) . In this novel lineage, mice have a reduced CD8 + T cell population (1±6% of splenocytes) due to the expression of the HHD transgene as the only MHC class I molecule. However, this reduced number of CD8 + T cells does not constrain the width of the repertoire (18, 22) .
The non-immunized HBsAg/HLA-A2 mice are tolerant to the viral antigen encoded by the transgene. They have neither anti-HBs antibody nor liver damage (normal ALT level, data not shown).
Induction of HBs-speci®c CD8 + T cells in HBsAg/HLA-A2 mice
In the HBsAg transgenic parental E36 lineage we have previously shown that DNA immunization with a plasmid encoding HBsAg (pCMV-S2.S) was able to overcome tolerance to this antigen (6) . However, in this C57 BL/6 genetic background, only one H-2 b -restricted epitope was de®ned in mice immunized with HBsAg (23) . In contrast, HBs-speci®c, HLA-A2-restricted epitopes were extensively studied both in acutely HBV-infected humans and in mice transgenic for HLA-A2 (18, 24, 25) . Therefore, the HBsAg/HLA-A2 double-transgenic mice could be useful to further de®ne the functions and the ®ne speci®city of CD8 + T cells involved in breaking tolerance to HBsAg after DNA-based immunization.
After two injections of pCMV-S2.S plasmid, a high frequency of HBV-speci®c IFN-g-secreting CD8 + T cells was induced in HBsAg + and HBsAg ± mice (Fig. 1A) . Spot-forming CD8 + T cells reacting with two HLA-A2-restricted epitopes (HBs 183±191 and HBs 348±357 ) were detected in all animals of both groups without any in vitro ampli®cation. These two epitopes have been previously referred to as superdominant, due to the high rate of speci®c response induced in all pCMV-S2S-immunized HLA-A2 mice (18) . Higher frequencies of CD8 + T cells speci®c for the peptide HBs 348±357 were induced by DNA-based immunization in HBsAg + compared to HBsAg ± mice (0.8 and 0.4% of CD8 + T cells respectively, Fig. 1A ). These CD8 + T cells were long lasting as they were still detected 10 weeks postimmunization (data not shown). No signi®cant response was observed in non-immunized mice even in animals expressing HBsAg (see Fig. 1A ).
To analyze the capacity of CD8 + T cells from pCMV-S2.Simmunized HBsAg + mice to recognize epitopes derived from the processing of endogenously produced antigen, we performed IFN-g ELISPOT with recombinant vaccinia virus expressing the large HBV envelope protein. We have previously shown that infection of splenocytes with this virus allowed presentation of epitopes recognized by CD8 + T cells only (18) . Comparison of responses obtained from either HBsAg ± or HBsAg + mice provided evidence that CD8 + T cells primed in the periphery by DNA immunization recognized murine spleen cells presenting epitopes derived from the endogenous processing with the same ef®ciency (Fig. 1B) .
In addition to the secretory function of CD8 + T cells induced by DNA immunization in HBsAg + and HBsAg ± HLA-A2 mice, their ability to mediate lysis was also studied. Following 1 week of in vitro peptide stimulation, splenocytes from either HBsAg + or HBsAg ± HLA-A2 immunized mice were able to lyse autologous targets presenting the two superdominant epitopes (i.e. HBs 183±191 and HBs 348±357 ) with comparable ef®ciency (Fig. 1C) . Because a high frequency of CD8 + T cells recognizing epitopes derived from HBsAg was found in the periphery, we asked if these cells could have mediated the lysis of liver cells. No signi®cant elevation of transaminase activities was found in sera taken sequentially after DNA immunization or after booster injection (data not shown).
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In this new animal model DNA immunization with pCMV-S2.S vector induced peripheral HBV-speci®c cells with the full characteristics of autoreactive T cells: (i) high frequency, (ii) secretion of IFN-g, (iii) recognition of endogenously processed antigen and (iv) in vitro lytic activity. However, these cells seemed unable to lyse transgene-expressing liver cells. These results suggest that spleen-derived CD8 + T cells primed by DNA-based immunization, although fully competent in vitro, were functionally tolerant in vivo to the viral antigen expressed by liver cells.
Ability of HBsAg/HLA-A2 mice to develop T h 1 response
To measure CD4 + T cells primed by DNA immunization and hence determine whether the inef®cient function of CD8 + T cells could be associated with a defect in T h response, we performed IFN-g or IL-4 ELISPOT using either HBsAg recombinant particles or I-A b -restricted epitope present in the preS2 domain of the middle HBV envelope protein as stimulating antigens. These antigens were previously shown to stimulate CD4 + T cells in particular (18) . In HBsAg ± mice, IFNg-secreting CD4 + T cells recognizing native antigen or preS2-speci®c I-A b -restricted peptide were induced by pCMV-S2.S immunization, whereas in HBsAg + mice, neither HBs-speci®c IFN-g-secreting nor IL-4-secreting CD4 + T cells were detected ( Fig. 2A and data not shown) . ELISPOT assay performed with T cells from non-immunized mice did not detect speci®c CD4 + T cells.
To determine if the failure in induction of the HBs-speci®c CD4 + T cell response in HBsAg/HLA-A2 mice immunized with HBsAg-encoding DNA was due to a global defect in the CD4 + T cell response, we immunized mice with a plasmid encoding an irrelevant antigen. HBsAg + and HBsAg ± HLA-A2 transgenic mice were injected twice with pMAS-core plasmid encoding the HBV core protein. The HBsAg + mice do not express this antigen because the viral genome used as a transgene has been deleted of the core gene (11) . IFN-g-secreting CD4 + and CD8 + T cells were tested by ELISPOT assay using HBc 128±140 -and HBc 18±27 -derived peptides as stimuli, corresponding to the well-described I-A b -and HLA-A2-restricted epitopes respectively (26, 27) . Two weeks after the second injection, all mice mounted core-speci®c CD4 + and CD8 + T cell responses. The frequencies of core-speci®c CD4 + and CD8 + T cells were not signi®cantly different between HBsAg + and HBsAg ± mice (Fig. 2B) . These results suggested that in HBsAg/HLA-A2 transgenic mice there is a speci®c defect in priming HBs-speci®c CD4 + T cells after pCMV-S2.S immunization. This defect could be due to a speci®c tolerance to HBsAg in the CD4 + T cell compartment.
To further analyze if the CD4 + T cell tolerance was spread over all preS2-speci®c epitopes, we studied the T h 1 response induced by pCMV-S2.S immunization towards the complete preS2 region of the HBV middle protein. For this purpose we used overlapping peptides covering the preS2 region as stimulator peptides in ELISPOT assay (Fig. 3A) . We analyzed the T h 1 response after two pCMV-S2.S immunizations in HBsAg ± and HBsAg + HLA-A2 transgenic mice. As described above, HBsAg ± mice mounted a response against native HBsAg and the dominant I-A b preS2 peptide (preS2 126±138 ) (Fig. 3B) , whereas HBsAg + mice did not. In addition, SFC were detected using the preS2 109±134 peptide. Regarding the HBsAg + HLA-A2 transgenic mice, a T h 1 response speci®c for preS2 139±163 peptide could be detected in four of seven HBsAg + HLA-A2 transgenic tested mice following DNA-based immunization. In contrast, in HBsAg ± HLA-A2 transgenic mice, a speci®c response against preS2 139±163 peptide was detected in only two of nine mice and at a lower frequency. These results suggest that CD4 + T cells speci®c for the subdominant epitope could be stimulated by DNA immunization in HBsAg + HLA-A2 transgenic mice, whereas CD4 + T cells speci®c for dominant epitopes were tolerized.
HBsAg clearance did not occur in HBsAg/HLA-A2 mice following DNA-based immunization
In the E36 parental lineage of HBsAg transgenic mice we have previously shown that HBs-speci®c CD4 + and CD8 + T cells induced by DNA immunization were able to control HBs mRNA expression in hepatocytes via an IFN-g-dependent mechanism (28) . In addition, CD4 + T cells also contributed to the clearance of circulating HBsAg in the sera by providing help to HBs-speci®c B cells. To determine if pCMV-S2.S-primed CD8 + and CD4 + T cells have the same antiviral effect in the context of another MHC class I molecule, HBsAg/HLA-A2 mice were bled and the HBsAg concentration in the sera was measured by speci®c ELISA. Non-immunized HBsAg/HLA-A2 mice were followed as a control. A natural decrease of HBsAg in the sera related to age of mice was observed in the control group (20) (Fig. 4) . A signi®cant 2-fold decrease in circulating HBsAg was observed in DNA-immunized mice during the ®rst 2 weeks following DNA immunization and then the rate of decrease of the antigen did not differ from controls (Fig. 4) . However, the HBsAg in the sera of DNA-immunized mice remained consistently lower than in non-immunized transgenic mice. Even immunization followed by a booster injection did not induce the complete clearance of HBsAg, but only led to a drop in the HBsAg level after each injection (data not shown). Northern blot analysis performed on mRNA extracted from liver of DNAimmunized mice showed no decrease in HBV mRNA either (data not shown).
Thus, in HBsAg/HLA-A2 transgenic mice, HBs-speci®c IFN-g-secreting CD8 + T cells present in the periphery are unable to control viral mRNA expression in the liver and this correlated with HBsAg persistence in the sera. 
Clearance of HBsAg following adoptive transfer of speci®c CD4 + T cells occurred only in irradiated mice
In HBsAg/HLA-A2 transgenic mice, DNA immunization was not ef®cient at inducing the clearance of viral antigen and that correlated with a partial tolerization of HBs-speci®c CD4 + T cells (see Figs 2 and 3) . To further de®ne the role of CD4 + T lymphocytes in this model, we performed adoptive transfer of pCMV-S2.S-primed CD4 + T cells from HBsAg ± HLA-A2 transgenic mice into HBsAg + HLA-A2 transgenic mice as recipients.
CD4 + T cells (5±6 Q 10 6 ) puri®ed from either pCMV-S2.Simmunized or naive HBsAg ± mice were injected i.v. into their sublethally or non-irradiated HBsAg + littermates. When HBsspeci®c CD4 + T cells were injected in non-irradiated HBsAg + HLA-A2 transgenic mice as control, no signi®cant decrease of circulating HBsAg was observed (Fig. 5) . Although competent for IFN-g secretion and for recognition of different HBs-related epitopes, these HBs-speci®c CD4 + T cells were unable to help for the production of anti-HBs antibodies and for the subsequent clearance of HBsAg in non-irradiated mice.
Interestingly, in irradiated mice receiving CD4 + T cells puri®ed from pCMV-S2.S-immunized mice, a dramatic decrease of circulating antigen was observed in all mice from weeks 5 to 10 and the HBsAg level remained negative for at least 12 weeks (Fig. 5) . Transfer of only 1200 HBs-speci®c IFN-g-secreting CD4 + T cells per mouse, as quanti®ed by ELISPOT performed on donor cells, was suf®cient to mediate antigen clearance. One of the mice receiving CD4 + T cells from pCMV-S2.S-immunized mice had a slower decrease in HBsAg level, which could be ascribed to a partial loss of T cells at the time of injection or to the highest level of HBsAg in serum among recipient mice at the day of transfer. No signi®cant decrease of the HBsAg level was observed in mice receiving unprimed CD4 + T cells. The immune responses of mice receiving CD4 + T cells were monitored. At week 12 post-transfer, no CTL were detected in recipient mice receiving either pCMV-S2.S primed or unprimed CD4 + T cells. In contrast, speci®c antibodies were detected from week 5 posttransfer in all mice receiving HBs-speci®c CD4 + T cells (data not shown). The long time required (5 weeks) for the clearance of the antigen may correspond to the time needed for B cell restoration and their activation by circulating HBsAg together with the transferred CD4 + T cells.
These results show that HBs-speci®c CD4 + T cells primed in a non-transgenic environment could break peripheral tolerance in this model. The CD4 + T cells primed by DNA immunization in HBsAg ± mice did not activate speci®c cytotoxic T cells, but acted by helping B cells to produce speci®c antibodies in the recipient HBsAg transgenic mice. Nevertheless, the HBs-speci®c CD4 + T cells require sublethal irradiation to mediate the clearance of circulating antigen.
Irradiation of HBsAg/HLA-A2 mice restored an ef®cient T cell response
We further investigated if irradiation could restore in vivo the antiviral functions of T cells primed by DNA-based immunization in HBsAg/HLA-A2 mice. DNA immunization was performed 2 days after sublethal g-irradiation of mice and HBsAg levels were measured. The pMAS-core plasmid was injected in HBsAg + irradiated mice as a positive control for immune response induction. No HBs-speci®c T lymphocytes were detected by ELISPOT in mice receiving pMAS-core DNA. However, IFN-g-secreting CD4 + and CD8 + T cells speci®c for core antigen were detected 6 weeks after immunization (see Fig. 2B and data not shown). This indicates that restoration of the T lymphocyte population had occurred in irradiated animals, allowing initiation of CD4 + and CD8 + T cells responses following immunization with an irrelevant antigen. This also shows that production of antigen by cells transfected by plasmid DNA lasted long enough to activate new thymic emigrant cells.
No signi®cant decrease of HBsAg was observed during the ®rst 2 weeks in mice that were irradiated prior to pCMV-S2.S immunization (Fig. 6) . Then, HBsAg strongly decreased in the sera of most mice and complete clearance of HBsAg was even observed in half of them ( Table 1 ). The delay in the response may correspond to the restoration and priming of a new lymphocyte population after irradiation. In contrast, in irradiated mice immunized with the pMAS-core irrelevant plasmid and in non-irradiated mice immunized with pCMV-S2.S, the HBsAg level remained constant in the sera. In irradiated mice immunized with pCMV-S2.S DNA, HBs-speci®c IFN-g-secreting CD8 + T cells were present from week 6 to 12 postimmunization in all tested mice (Table 1 ). Regarding the induction of an HBs-speci®c T h 1 CD4 + response, mice could be classi®ed in two groups. HBs-speci®c CD4 + T cells were detected by ELISPOT assay at the time of sacri®ce (i.e. 6 or 12 weeks) in two mice, while no HBs-speci®c CD4 + T cells were detected in the three other mice. Interestingly, the serum concentration of HBsAg in the ®rst group was <10 ng/ml or undetectable and anti-HBs antibodies were detected (Table 1) . These results show that irradiation of mice prior to immunization leads to the emergence of an immune response with antiviral properties. Clearance of HBsAg in the sera and concomitant detection of a preS2-speci®c CD4 + T cell response in individual mice suggests that these cells provided help to B cell for anti-HBs antibody production.
Injection of immunostimulatory sequences interfered with T cell tolerance in DNA-immunized HBsAg/HLA-A2 mice
Because total-body irradiation was described to act as a proin¯ammatory signal marked by production of tumor necrosis factor (TNF)-a, IL-6 and IL-1, we next investigate if injection of We used immunostimulatory sequences containing CpG motifs that we had previously shown to strongly activate B cells to produce antibodies, and to induce T h 1 cytokines secretion such as TNF-a, IL6, IFN-g and IL-12 (17) . Non-CpG ODN were used as negative controls. HBsAg + mice were injected twice with pCMV-S2.S DNA to induce a high frequency of CD8 + T cells. One week after the booster injection CpG ODN were injected i.p. In mice receiving CpG ODN, a decrease in the HBsAg level was observed 1 week after the injection (Fig. 7A) . In two out of ®ve mice, HBsAg became undetectable 2±3 weeks after CpG ODN injection. In the three other mice HBsAg decreased signi®cantly, but remained at an intermediate level for at least 4 weeks. In control mice receiving either DNA vaccine and non-CPG ODN or CpG ODN alone, a slow decrease in circulating HBsAg was observed ( Fig. 7B and C) . Immunization with DNA followed by CpG or non-CpG ODN injections induced production of antiHBs antibodies (Fig. 7D and E) , but higher titers were observed in mice receiving CpG ODN (Fig. 7D) . The adjuvant effect of non-CpG ODN on B cells was previously observed in other studies and could be due to some adjuvant properties of the ODN phosphorothioate backbone (17, 29) . In addition, antibodies were higher in mice with a strong decrease in HBsAg.
Frequencies of HBs-speci®c CD8 + and CD4 + T cells were monitored by ELISPOT assays 4 weeks after ODN injection. In the groups of mice receiving either the CpG ODN or the nonCpG ODN after pCMV-S2.S immunization, the frequency of speci®c CD8 + T cells was similar for both dominant HLA-A2-restricted epitopes (Fig. 8A) . This result shows that CpG ODN injection post-immunization has no major effect on the magnitude of the CD8 + T cell response.
No signi®cant HBs-speci®c CD4 + T cells were induced in mice receiving control ODN, as the number of spots remained under the threshold level. In contrast, in mice receiving the CpG ODN, signi®cant frequencies of IFN-g-secreting CD4 + T cells were detected in three of ®ve immunized mice (Fig. 8B ). This helper response was detected using whole HBsAg particles and preS2-derived peptide in individual mice. Detection of speci®c CD4 + T cells correlated with the strongest decrease of circulating antigen.
Thus, in HBsAg/HLA-A2 transgenic mice, DNA immunization combined with CpG ODN injection induced a decrease of circulating HBsAg and a concomitant production of speci®c antibodies, which correlated with speci®c CD4 + T cell detection. In this model, a pro-in¯ammatory signal is required for the emergence of a detectable CD4 + T cell response that was inhibited in the periphery by the presence of a high level of HBsAg.
Discussion
We have developed a novel murine model for HBV chronic infection, HBsAg/HLA-A2 double-transgenic mice, in order to a HBsAg concentration measured in serum at the time of sacri®ce. b IFN-g-secreting CD4 + T cells/10 6 spleen cells measured by ELISPOT performed on fresh splenocytes using the preS2-derived I-A brestricted peptide (HBs 126±138 ) as stimulator antigen. Ten spots were considered as the cut-off value.
c IFN-g-secreting CD8 + T cells/10 6 spleen cells measured by ELISPOT performed on fresh splenocytes with the HBs-derived HLA-A2-restricted peptide (HBs 348±357 ) as stimulator antigen. Ten spots were considered as the cut-off value.
d Mice killed at 12 weeks post-immunization (all other mice killed 6 weeks post-immunization). (i) study the tolerance to HBsAg expressed in the liver from before birth and highly secreted into blood, and (ii) have an animal model closely related to neonatally acquired chronic infection in which therapeutic approaches could be assessed. In this model, tolerance of both T cell subsets and their synergy to clear the circulating viral antigen were studied.
Contrary to most of the studies performed using mice expressing a unique TCR directed to a self-epitope encoded by a transgene, the HBsAg/HLA-A2 transgenic mice displayed a wide HLA-A2 MHC class I-restricted CD8 + T cell repertoire, as previously shown in single HLA-A2 transgenic mice (18, 22, 30) . They also display the natural H-2 b MHC class II-restricted CD4 + T cell repertoire. Because they express the viral transgene from birth and because the amounts of HBsAg in the serum are similar to those found in humans, the HBsAg/HLA-A2 animal model will be useful to understand how the high concentration of HBsAg in the sera of HBV chronic carriers regulates the immune response, in turn impairing the viral clearance.
HBV-speci®c T cell responses have been related to clearance of the virus in acutely infected patients (31) . It was shown in different models that replication of HBV or other hepadnavirus replication is regulated by T h 1 cytokines such as IFN-a/b, IFN-g and TNF-a (32±34). In HBsAg transgenic mice, in duck infected at birth with DHBV and in WHBV-infected woodchuck, DNA-based immunization was shown to induce strong T h 1-type responses that resulted in viral elimination (6, 35, 36) .
In the novel humanized model for chronic hepatitis B infection described here, DNA immunization with a plasmid encoding HBsAg induced a high frequency of HBV-speci®c CD8 + T cells in the periphery even in the presence of a high level of antigen in the sera. These T cells shared the same characteristics with those detected in patients resolving HBV infection (37, 38) . However, these CD8 + T cells were unable to exert their antiviral effector functions in vivo against hepatocytes expressing this antigen and thus failed to control viral expression in the liver. Inducing such CD8 + T cells could be considered as a mechanism of silencing antiviral immune responses during chronic infection.
In our animal model, it is clear that thymic clonal deletion of autoreactive CD8 + T cells does not occur since HBs-speci®c CD8 + T lymphocytes were primed by DNA-based immunization despite the presence of a high level of circulating HBsAg. The CD8 + T cell functions were very similar to those induced by the same immunization protocol in an HBsAg ± transgenic littermate. The rupture of CD8 + T cell tolerance by DNA-based immunization could result from antigen presentation by APC in the muscle after cross-priming (39), direct production of antigen in APC by plasmid transfection (40) or from conditioning of APC by CpG immunostimulatory sequences present in the plasmid backbone (41) . The only difference seen in the DNA-immunized HBsAg + mice compared to their HBsAg ± counterparts was an enhancement of their frequency for the two dominant epitopes (Fig. 1A) . This increased frequency could be explained by stimulation of DNA-primed T cells by HBsAg-derived peptides presented on transgenic hepatocytes, by the MHC class I alternative pathway for processing and presentation of exogenous HBsAg in peptides (42) or by activation of pre-existing, but anergized HBs-speci®c CD8 + T cells in HBsAg + mice. However, this difference was not observed when recombinant vaccinia virus expressing HBV envelope proteins was used in the ELISPOT assay (Fig. 1B) . This suggests that additional envelope-derived epitopes presented by cells infected with the vaccinia virus were recognized in HBsAg ± mice. In the HBsAg/HLA-A2 mice, the induction of cytotoxic CD8 + T cells in the periphery does not result in autoimmune disease nor in an ef®cient control of the transgene expression as was previously observed in other mouse models for HBV chronic infection (6, 43, 44) . Compared to the HBsAg parental transgenic lineage (6) , this discrepancy could be ascribed to the low level of MHC class I molecules on the cell surface due to HHD transgene expression (10) resulting in a less ef®cient recognition between CD8 + T cells and hepatocytes expressing antigen. However, a defect in presentation of the two dominant epitopes described here on transgenic hepatocytes cannot be formally excluded. Another property of the HBsAg/HLA-A2 mouse is its low number of total CD8 + T cells (10) that is clearly below the threshold required for ef®cient control of HBV mRNA expression in the liver (44, 45) . Remarkably, we show here that this inef®cient CD8 + T cell response was also associated with a defect in the CD4 + T cell response.
In the CD4 + T cell compartment, the tolerance appeared to be more established compared to CD8 + T cells. Although a shift from a T h 1 to T h 2 response was shown to be a mechanism of tolerization to prevent destruction of the organ in models in which T h 1 responses are related to autoimmune disease (46± 48), neither T h 1 nor T h 2 HBs-speci®c CD4 + T cells were detected by ELISPOT in DNA-immunized HBsAg/HLA-A2 mice. Nevertheless, HBs-speci®c CD4 T cell responses could be restored by sublethal irradiation or CpG ODN injection in the DNA-immunized HBsAg/HLA-A2 mice, resulting in an ef®cient antiviral immune response and subsequent clearance of circulating HBsAg. This result indicates that HBsspeci®c CD4 + T cells were not clonally deleted in thymus, but rather tolerized in the periphery. Irradiation or CpG ODN injection have been involved in breaking tolerance of T cells to viral antigen (3, 49, 50) . Irradiation mediates massive cell apoptosis and in¯ammation resulting in part in T cell migration into the liver (50). Since CpG motifs are known as proin¯ammatory mediators, they could have mimicked effects of g-irradiation (3). One possible hypothesis is that, in immunized HBsAg/HLA-A2 mice, pro-in¯ammatory mediators conditioned the microenvironment of the liver leading to migration of DNA-primed speci®c CD8 + T cells. This migration could result in the partial control of the transgene expression by IFNg secreted by CD8 + T cells and that correlates with the transient sharp decrease of HBsAg observed in the serum after DNA-based immunization (see Fig. 4 ). After sublethal irradiation or CpG ODN injection, emergence of the CD4 + T cell response was only observed in mice displaying a strong decrease of viral antigen in serum. These results suggest that a high level of circulating HBsAg maintained CD4 + T cell tolerance. These CD4 + T cells might have a crucial role in maintaining the number or in post-licensing HBs-speci®c peripheral CD8 + T cells (51, 52) . CD4 + T cells have also been involved in helping activated CD8 + T cells to migrate into the liver and to secrete regulatory cytokines (51) . In addition, we showed here using adoptive transfer experiments that CD4 + T h cells activate HBsAg-speci®c B cells to produce anti-HBs antibodies. These antibodies could, in turn, mediate the decrease of HBsAg in serum of mice by immune complex formation.
In this novel animal model for HBV chronic carriers, we have shown that the role of circulating HBsAg in the maintenance of T cell tolerance was crucial. Although induced in the periphery by DNA immunization, HBs-speci®c polyclonal CD8 + T cells displayed no effector functions in the liver. In patients, a lowfrequency population of HBs-speci®c CD8 + T cells with altered tetramer binding and surviving in the presence of a high quantity of HBsAg was recently described (53) . In our animal model, restoration of CD4 + T cells via irradiation or CpG ODN injection correlates with the clearance of the tolerizing antigen. This is in agreement with the reconstitution of CD4 + T cell activity observed in chronically infected patients after successful antiviral treatment (54) . Design of immunotherapy should consider these points. Combining control of replication and decrease in antigen load with induction of HBV-speci®c CD4 + and CD8 + T cells by vaccine therapy could represent an issue to mediate an ef®cient immune response in chronically infected patients.
